Share This Page
Litigation Details for Sanofi v. First Time US Generics LLC (D. Del. 2014)
✉ Email this page to a colleague
Sanofi v. First Time US Generics LLC (D. Del. 2014)
| Docket | 1:14-cv-00293 | Date Filed | 2014-03-06 |
| Court | District Court, D. Delaware | Date Terminated | 2016-04-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,323,493; 8,318,800; 8,410,167; 8,602,215 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sanofi v. First Time US Generics LLC
Details for Sanofi v. First Time US Generics LLC (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-03-06 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Sanofi v. First Time US Generics LLC (1:14-cv-00293): Litigation Summary, Claims at Issue, and Generic Entry Risk
Sanofi sued First Time US Generics LLC in the District of New Jersey (case no. 1:14-cv-00293). The docket identifier is provided, but the underlying patent list, asserted claims, filing dates, Markman schedule, summary-judgment posture, and settlement or judgment terms are not included. Without the case filings (complaint, answer, infringement contentions, PTAB status if any, and any published settlement/judgment order), a complete, accurate litigation summary and analysis cannot be produced.
What is the case 1:14-cv-00293 about and what patents did Sanofi assert?
A litigation summary requires, at minimum, the asserted Orange Book patents, the specific listed FDA product(s), and the claims of infringement alleged in the complaint. Those data are not present in the prompt.
Which Orange Book patents were listed and challenged?
A credible answer depends on the specific Orange Book NDA(s) and the patents asserted in the complaint (often a set of composition-of-matter, formulation, method-of-use, and/or manufacturing patents). Those asserted patent numbers and expiration dates are not provided.
What causes of action were pleaded (35 U.S.C. § 271(e)(2), declaratory judgment, injunction)?
These must be read from the complaint. The prompt does not include the complaint allegations or counts.
What generic product did First Time US Generics file an ANDA for?
To analyze entry risk, the ANDA filer’s abbreviated application, the applicant’s proposed label, strength(s), dosage form(s), and paragraph IV basis must be identified. The prompt does not include the ANDA number, reference product, strength(s), or the specific FDA notice letter.
What paragraph IV certification did First Time US Generics make?
Paragraph IV theory and carveouts drive the infringement scope. No certification details or notice-letter dates are provided.
Did the litigation concern generic design-around amendments or carveouts?
Design-around facts and any FDA labeling carveouts require docket documents or filings (e.g., amended contentions, Rule 16 scheduling orders). Those are not provided.
What does the case docket show on timing: motions, hearings, and outcomes?
An evidence-based timeline needs docket events such as motions to dismiss, claim construction (Markman), summary judgment, trial date(s), and any final judgment or dismissal. The prompt provides only the case number.
Key procedural milestones that typically matter
- Case filing and service
- Answer and any jurisdictional defenses
- Initial infringement contentions and noninfringement/invalidity positions
- Claim construction order and deadlines
- Expert discovery schedule
- Summary judgment rulings
- Settlement dismissal dates or consent judgments
No such dates or rulings are included in the prompt.
How strong was Sanofi’s patent position in this litigation?
Strength analysis depends on: (1) asserted claim scope, (2) claim construction outcomes, (3) infringement evidence (product labeling, manufacturing process, ANDA exhibits), (4) invalidity arguments (anticipation/obviousness, written description/enablement), and (5) any PTAB-related estoppel. None of these details are present.
What claim constructions did the court adopt?
Markman constructions often decide the case. Court constructions are not provided.
What invalidity theories were used (anticipation, obviousness, 112 issues)?
Invalidity theories and references must be listed. They are not provided.
Did the court reach infringement, invalidity, or both?
Final posture determines business impact: injunction risk, launch design constraints, and licensing posture.
What was the dispositive outcome?
The prompt does not include whether there was a final judgment, summary judgment ruling(s), consent judgment, or settlement dismissal.
Was there an appellate path?
If there was an appeal, dates and case numbers are needed. None are provided.
Was there a settlement agreement and what did it require?
A settlement analysis requires the agreement terms or at least court-filed settlement facts: generic launch date, sunset payments, field-of-use restrictions, carveout labeling, and any stipulated dismissal with or without prejudice.
When did the parties settle?
Settlement dates and effectiveness dates are not provided.
Did settlement include license grants or covenants not to sue?
License scope and duration are not provided.
How does this litigation affect potential generic entry timing?
Entry timing is driven by: (1) patent expirations, (2) exclusivity (NCE/5-year/7-year/Biologic exclusivity where relevant), (3) whether patents were held valid/infringed, and (4) any settlement launch “at risk” date.
Patent expiration vs. litigation outcome
Without asserted patents and their expiration dates, no exclusivity timeline can be computed.
Launch “at risk” vs. permitted entry
Without the settlement/judgment status, the entry risk cannot be characterized.
What is the Orange Book status of the relevant patents?
Orange Book status requires listing each asserted patent and whether it is listed for the NDA (and for which dosage forms and strengths), including expiration and any pediatric exclusivity.
No NDA, product, or patent list is included.
Which patents are still listed and what are their projected expirations?
No patent numbers or expiration dates are provided.
Which companies are involved beyond Sanofi and First Time US Generics?
Litigation often includes NDA holder(s), relevant subsidiaries, or other co-plaintiffs and counsel from multiple sides. It also sometimes references other ANDA filers or related cases.
No additional party details are provided.
Are there related cases in the same or different districts?
Related actions affect scope and whether courts coordinate claim construction. The prompt does not include related case citations.
How does this case compare with other Sanofi v. generic litigations?
Competitive landscape analysis depends on other case outcomes and whether Sanofi consistently wins on similar patent families or enforcement strategies.
No comparative case set is provided.
Were similar patents asserted in other cases?
Not provided.
Practical business implications: what are the generic/IP barriers if you are evaluating entry?
A barrier assessment needs:
- whether Sanofi obtained injunction or favorable validity rulings,
- whether remaining patents create blocking positions,
- whether design-around was permitted,
- whether manufacturing and labeling are constrained.
None of these underlying facts are provided.
What are the likely design-around constraints?
These flow from claim construction and claim scope. Not provided.
What manufacturing and labeling issues drive discovery?
These are specific to ANDA exhibit comparisons and are not included.
Key Takeaways
- The case identifier 1:14-cv-00293 is provided, but litigation facts needed for an accurate infringement/invalidity and procedural-outcome summary are not included.
- A defensible litigation summary and business-impact analysis cannot be produced without the asserted patent list, court rulings, and docket event outcomes.
FAQs
- What patents were asserted by Sanofi in 1:14-cv-00293?
- Did First Time US Generics’ ANDA trigger a paragraph IV certification in this case?
- What claim construction results affected the infringement analysis?
- Was there a settlement, consent judgment, or dismissal, and what launch terms were agreed?
- Which court orders controlled the timeline for generic entry risk?
References
- U.S. District Court, District of New Jersey. Case No. 1:14-cv-00293 (Sanofi v. First Time US Generics LLC).
More… ↓
